pyrrolopyrimidine profile

pyrrolopyrimidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	577022
SCHEMBL ID	63453
SCHEMBL ID	7854
SCHEMBL ID	22959928
MeSH ID	M0519940

Synonym
272-50-4
pyrrolopyrimidine
1,4,6-triazaindene
5h-pyrrolo(3,2-d)pyrimidine
5h-pyrrolo[3,2-d]pyrimidine
FT-0650230
A818976
452-20-0
AKOS006326646
AM20090338
PB22262
SCHEMBL63453
KCTZOTUQSGYWLV-UHFFFAOYSA-N
SCHEMBL7854
1h-pyrrolo[3,2-d]pyrimidine
J-517588
mfcd09834826
CS-W022388
DS-10602
alpha-[1-(t-butylamino)ethyl]-2,5-dimethoxybenzylalcoholhydrochloride
SCHEMBL22959928
SY097782
EN300-697544
DTXSID401346584
1,4,6-triaza-1h-indene

Excerpt	Reference	Relevance
"Pyrrolopyrimidines are an important class of natural products with a broad spectrum of biological activities, including antibacterial, antifungal, antiviral, anticancer or anti-inflammatory. "	( Identification of a Biosynthetic Gene Cluster Responsible for the Production of a New Pyrrolopyrimidine Natural Product-Huimycin. Luzhetskyy, A; Myronovskyi, M; Nadmid, S; Shuai, H, 2020)	2.22

Excerpt	Reference	Relevance
" It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS."	( Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Chresta, CC; Cosulich, S; Crafter, C; Cross, D; Davies, BR; Dudley, P; Gao, B; Greenwood, H; Ji, Q; Lane, C; Li, J; Luke, R; Maynard, J; Ogilvie, D; Page, K; Pass, M; Ricketts, SA; Watson, R; Yates, J; Yu, DH; Zhang, J, 2012)	0.38
" To enhance the pharmacokinetic (PK) profile of this compound, we conducted chemical modifications into its N-5 side chain and conversion of the chemically modified compounds into their salts."	( Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. Banno, H; Ikeda, Y; Ishikawa, T; Kamiguchi, H; Kamiyama, K; Kawakita, Y; Miki, H; Miwa, K; Ohta, Y; Seto, M; Tamura, T; Tanaka, T; Yusa, T, 2012)	0.38
" However, the search for distinct safety and pharmacokinetic (PK) properties has motivated our exploration of alternative scaffolds."	( 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors. Arnold, SLM; Barrett, LK; Choi, R; Fan, E; Golkowski, M; Huang, W; Hulverson, MA; Maly, DJ; McCloskey, MC; Merritt, EA; Ojo, KK; Van Voorhis, WC; Vidadala, RSR; Whitman, GR, 2018)	0.48

Excerpt	Relevance	Reference
" Once weekly dosing brings greater patient compliance and more stable glycemic control."	( Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool. Dou, W; Guo, J; Hu, W; Huang, H; Li, M; Ma, Y; Xie, H; Zeng, S; Zhao, N; Zhao, X; Zhou, Q; Zhou, Y, 2020)	0.56

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (6.74)	29.6817
2010's	65 (73.03)	24.3611
2020's	18 (20.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (1.09%)	5.53%
Reviews	5 (5.43%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	86 (93.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
purine 1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.	7.08	1	0	purine
pyrazole 1H-pyrazole : The 1H-tautomer of pyrazole.	2.21	1	0	pyrazole
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.5	2	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.15	1	0
benzimidazole 1H-benzimidazole : The 1H-tautomer of benzimidazole.	2.21	1	0	benzimidazole; polycyclic heteroarene
aniline [no description available]	2.25	1	0	anilines; primary arylamine
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.15	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	9.5	88	1	pyrrole; secondary amine
furan furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.	2.21	1	0	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.08	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	2.21	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrimidine pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.	7.15	1	0	diazine; pyrimidines	Daphnia magna metabolite
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	7.04	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
nsc 65346 sangivamycin: RN given refers to parent cpd. sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.	2.04	1	0	nucleoside analogue	protein kinase inhibitor
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.05	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.15	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.89	3	0	1,2,3-triazole
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	7.08	1	0	D-glucuronic acid	algal metabolite
erlotinib hydrochloride [no description available]	2.11	1	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
2-oxindole 2-oxindole: RN given refers to parent cpd; structure. indolin-2-one : An indolinone carrying an oxo group at position 2.	2.05	1	0	gamma-lactam; indolinone
calcein am calcein AM: a non-fluorescent compound cleaved to a fluorescent compound by non-specific intracellular esterases. calcein am : An organic heteropentacyclic compound that is calcein in which all four carboxy group hydrogens have been substituted by (acetyloxy)methoxy groups and the hyrodgens of the two hydroxy groups have been substituted by acetyl groups. It is a a non-fluorescent probe cleaved to a fluorescent probe by non-specific intracellular esterases.	2.15	1	0	2-benzofurans; acetate ester; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; xanthene dye	fluorochrome
7-deazapurine 7-deazapurine: structure in first source	3.17	1	0
su 11248 [no description available]	2.11	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
pyrazolopyridine pyrazolopyridine: act as competitive antagonists of brain adenosine A1 receptors	2.5	2	0
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	3.17	1	0	guanosines; purines D-ribonucleoside	fundamental metabolite
nucleoside q Nucleoside Q: A modified nucleoside which is present in the first position of the anticodon of tRNA-tyrosine, tRNA-histidine, tRNA-asparagine and tRNA-aspartic acid of many organisms. It is believed to play a role in the regulatory function of tRNA. Nucleoside Q can be further modified to nucleoside Q*, which has a mannose or galactose moiety linked to position 4 of its cyclopentenediol moiety.. queuosine : A nucleoside found in tRNA that has an additional cyclopentenyl ring added via an NH group to the methyl group of 7-methyl-7-deazaguanosine. The cyclopentenyl ring may carry other substituents.	3.62	2	0	7-deazaguanine ribonucleoside
archaeosine archaeosine: post-transcriptional modification seen in archaeal RNA; structure given in first source. archaeosine : A 7-deazaguanine ribonucleoside having 7-formamidino-7-deazaguanine as the nucleobase. It is found in the majority of archaeal tRNAs specifically at position 15 of the dihydrouridine loop (D-loop), a position not modified in either eukaryotic or bacterial tRNA.	3.17	1	0	7-deazaguanine ribonucleoside
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.21	1	0

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	4.16	5	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.16	5	0
Atypical Mycobacterial Infection, Disseminated [description not available]	2.41	1	0
Germinoblastoma [description not available]	2.25	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.25	1	0
Diabetes Mellitus, Adult-Onset [description not available]	2.25	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.25	1	0
Cancer of Colon [description not available]	2.25	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.25	1	0
Cryptosporidium Infection [description not available]	2.31	1	0
Cryptosporidiosis Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA.	7.31	1	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	2.31	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	2.31	1	0
Experimental Neoplasms [description not available]	2.15	1	0
Diffuse Large B-Cell Lymphoma [description not available]	2.15	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.15	1	0
Alloxan Diabetes [description not available]	2.17	1	0
Cancer of Prostate [description not available]	5.34	4	1
HIV Coinfection [description not available]	3.09	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	5.34	4	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.09	1	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.17	1	0
Coxsackie Virus Infections [description not available]	2.21	1	0
Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.	2.21	1	0
Angiogenesis, Pathologic [description not available]	2.17	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.08	1	0
Breast Cancer [description not available]	9.73	6	1
Breast Neoplasms Tumors or cancer of the human BREAST.	4.73	6	1
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	2.11	1	0
Cancer of Lung [description not available]	2.48	2	0
Cancer of Ovary [description not available]	2.11	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.48	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.11	1	0
Bone Loss, Osteoclastic [description not available]	2.04	1	0
Asthma, Bronchial [description not available]	2.05	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.05	1	0
Ache [description not available]	2.07	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.07	1	0
Ciliophora Infections Infections with protozoa of the phylum CILIOPHORA.	2.07	1	0
Glaucoma, Suspect [description not available]	2.08	1	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	7.08	1	0
Ocular Hypertension A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.	7.08	1	0
Cancer of Stomach [description not available]	2.07	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.07	1	0

pyrrolopyrimidine

Description

Cross-References

Synonyms (25)

Research Excerpts

Overview

Pharmacokinetics

Dosage Studied

Research

Studies (89)

Market Indicators

Research Demand Index: 33.17

Study Types

pyrrolopyrimidine

Description

Cross-References

Synonyms (25)

Research Excerpts

Overview

Pharmacokinetics

Dosage Studied

Research

Studies (89)

Market Indicators

Research Demand Index: 33.17

Study Types

Related Drugs (28)

Related Conditions (44)